TNFA: Rasio rega marang prakiraan pendapatan TNF Pharmaceuticals, Inc.
The expected P/S chart for TNF Pharmaceuticals (TNFA) on GURU.Markets reflects valuation dynamics, where the metric has reached the level of . Quotes are driven by the success of anti-aging drug development, bypassing market cycles. However, external risks of raw material supply disruptions from Asia could slow growth. Meanwhile, management is effectively coordinating trials of unique molecules to combat inflammation.
Rincian metrik keuangan lan pasar tnfpharma.com (TNFA)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas TNF Pharmaceuticals|TNFA - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang modal TNF Pharmaceuticals, Inc.|TNFA - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku TNF Pharmaceuticals, Inc.|TNFA - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan TNF Pharmaceuticals|Likuiditas cepet tnfpharma.com
- rincian asil keuangan lan kelipatan valuasi:
TNFA - Penghasilan resik|Proyeksi bathi mangsa ngarep TNF Pharmaceuticals|TNFA - Pangali P/E|Pangali Forward P/E TNF Pharmaceuticals, Inc.|TNFA - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA TNF Pharmaceuticals, Inc.|TNFA - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan TNF Pharmaceuticals|TNFA - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan tnfpharma.com|TNFA - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep TNF Pharmaceuticals
- informasi babagan volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:TNF Pharma TNFA
The reliability of an equity asset is determined by comparing market value with expected cash flows. The forward price-to-sales ratio measures business value per unit of future sales, which, given the R&D-oriented management of TNF Pharmaceuticals (TNFA), allows for an assessment of innovation investment efficiency by using the company's forward P/S valuation to identify whether the asset is overbought or undervalued relative to the industry context.
Pesaing TNF Pharmaceuticals
Haleon - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake KVUE (Kenvue Inc)|VRNA - Rasio rega marang prakiraan pendapatan|MENS (Jyong Bio) - Kapitalisasi marang prakiraan pendapatan|LGND: Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan AMRX (amneal.com)|Multiplikator forward rega marang pendapatan PRGO|ALVO: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|GLPG: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals)|Rega forward marang dodolan MNKD|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|PCRX - Multiplikator Forward P/S|ARS Pharma (SPRY) - Rasio rega marang prakiraan pendapatan|Theravance Corp - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Aquestive Therapeutics|Multiplikator forward rega marang pendapatan scPharma (SCPH)|Multiplikator Forward P/S TECX|Multiplikator Forward P/S Tonix Pharma (TNXP)|Multiplikator Forward P/S SXTC (China SXT Pharmaceuticals, Inc.)|EPRX - Multiplikator forward rega marang pendapatan|BioHarvest Sciences - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep invizyne.com|ORMP (oramed.com) - Multiplikator forward rega marang pendapatan|Entera Bio (ENTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S CPIX|Rasio kapitalisasi marang dodolan sing dikarepake quantumbiopharma.com|Multiplikator Forward P/S FGEN (FibroGen)|TELO - Multiplikator forward rega marang pendapatan|Rani Therapeutics Inc - Multiplikator Forward P/S|SNYR - Multiplikator Forward P/S|rallybio.com (RLYB) - Rasio rega marang prakiraan pendapatan|LEXX (Lexaria Bioscience Corp.) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Pulmatrix|Pheton (PTHL) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan APM (Aptorum Group Limited)|Rasio rega marang pendapatan sing dikarepake LYRA|Rasio rega marang prakiraan pendapatan Impact BioMedical Inc IBO|YCBD: Kapitalisasi marang prakiraan pendapatan|PainReform - Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan CYTO|LIPO: Multiplikator Forward P/S|OptiNose Corp (OPTN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|procapsgroup.com - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S PTPI|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|Multiplikator Forward P/S TFF Pharmaceuticals, Inc TFFP
